Literature DB >> 11677236

Molecular cross-talk between the TRAIL and interferon signaling pathways.

Chandan Kumar-Sinha1, Sooryanarayana Varambally, Arun Sreekumar, Arul M Chinnaiyan.   

Abstract

TRAIL/APO-2L induces apoptosis in a variety of transformed cells and has potential as an anti-cancer therapeutic. The physiologic role of TRAIL is presumably more complex than merely activating caspase-mediated cell death. To shed light into TRAIL-mediated signaling, we used DNA microarrays to profile gene expression mediated by TRAIL in breast carcinoma cells. Primary response genes induced by TRAIL included a number of known NF-kappaB-dependent genes such as cIAP2, A20, and E-selectin. Remarkably, global transcriptome analysis revealed that TRAIL also induced a cohort of genes related to the interferon-signaling pathway. Assessing interferon-induced gene expression suggested various points of interaction with the TRAIL signaling pathway. Interestingly, while we observed interferon-mediated up-regulation of TRAIL, we also demonstrated a concomitant TRAIL-mediated induction of interferon-beta. Combining TRAIL and interferon in vitro, synergistically induced apoptosis and caspase activation in breast cancer cells. Together, these data indicate multiple levels of molecular cross-talk between the two diverse cytokines with anti-tumor properties.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11677236     DOI: 10.1074/jbc.M107795200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  TRAIL, Bim, and thymic-negative selection.

Authors:  Shi-Jun Zheng; Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Modification of accessory molecule signaling.

Authors:  Mary K Crow
Journal:  Springer Semin Immunopathol       Date:  2006-05-16

4.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Authors:  Adrianos Nezos; Fotini Gravani; Anna Tassidou; Efstathia K Kapsogeorgou; Michael Voulgarelis; Michael Koutsilieris; Mary K Crow; Clio P Mavragani
Journal:  J Autoimmun       Date:  2015-07-14       Impact factor: 7.094

5.  Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.

Authors:  E V Shashkova; M N Kuppuswamy; W S M Wold; K Doronin
Journal:  Cancer Gene Ther       Date:  2007-11-09       Impact factor: 5.987

6.  G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

Authors:  Venugopalan Cheriyath; Keith B Glaser; Jeffrey F Waring; Rachid Baz; Mohamad A Hussein; Ernest C Borden
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 7.  Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.

Authors:  Quan Chen; Subrata Ray; Mohamad A Hussein; Gordan Srkalovic; Alexandru Almasan
Journal:  Leuk Lymphoma       Date:  2003-07

Review 8.  Genes and genomics of autoimmune inflammation: from Rel to TRAIL.

Authors:  Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

10.  Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.

Authors:  D Mahalingam; A Natoni; M Keane; A Samali; E Szegezdi
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.